ArticleCancer discovery2022
RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy.
Open access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.
0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed
5.2field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 112 citations in OpenAlex.
- Trial
- Overall Survival with Inavolisib inThe New England journal of medicine · 2025Trial
- CNS distribution and preclinical activity of the PI3K/AKT inhibitors inavolisib and ipatasertib in pediatric-type diffuse high-grade gliomas.Cancer chemotherapy and pharmacology · 2026Article
- Emerging Strategies Targeting the PI3K/AKT/mTOR Pathway in HR+/HER2- Advanced Breast Cancer.Drugs · 2026Review
- A renaissance in targeting the PI3K/AKT/mTOR pathway.Nature reviews. Drug discovery · 2026Review
- Synergistic Inhibition of Colorectal Cancer Growth by Combined PI3K and COX-2 Blockade in Cell Lines and Patient-Derived Organoids.Pharmaceutics · 2026Article
- Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancer.Nature communications · 2026Article
- Degrons and degradation signals beyond short linear motifs.Nature chemical biology · 2026Review
- Multiple patient-derived glioblastoma models reveal synthetic lethality through concurrent PI3K and CDK4/6 inhibition by blocking trans-active cooperation.Neuro-oncology · 2026Article
- PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Article
- Inavolisib-based Combination Therapy for the Treatment of PIK3CAMutated HR+/HER2- Breast Cancer: An Overview.Mini reviews in medicinal chemistry · 2026Review
- Conventional and alternative approaches for targeting PIK3CA and PTEN alterations in head and neck, breast, and other cancers.Advances in biological regulation · 2026Review
- PI3K/AKT/mTOR axis in vascular malformations: from molecular insights to targeted clinical trials.Orphanet journal of rare diseases · 2025Review
- Concurrent PIK3CA mutant promotes cachexia through inflammatory signaling in EGFR mutant lung cancer.Nature communications · 2025Article
- KRAS Codon-Specific Mutations Differentially Toggle PI3K Pathway Signaling and Alter Sensitivity to Inavolisib (GDC-0077).Molecular cancer therapeutics · 2025Article
- Optimizing endocrine adjuvant therapy in HR+/HER2- breast cancer: supplemental strategies and innovations.Annals of medicine and surgery (2012) · 2025Review
- Innovative Strategy for Enhanced Delivery of Anti-Fibrotic miR-150 via PDGFR-Targeted Exosomes for Fibrosis Treatment.Journal of Korean medical science · 2025Article
- Rational design of potent small-molecule SMARCA2/A4 degraders acting via the recruitment of FBXO22.Nature communications · 2025Article
- Precise regulation of RAS-Mediated PI3Kα activation: therapeutic potential of BBO-10203 in cancer treatment.Experimental hematology & oncology · 2025Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
27 authors at 6 institutions in 5 countries.
Kyung W SongDepartment of Discovery Oncology, Genentech, Inc., South San Francisco, California.
Kyle A EdgarDepartment of Discovery Oncology, Genentech, Inc., South San Francisco, California.
Emily J HananDepartment of Discovery Chemistry, Genentech, Inc., South San Francisco, California.ORCID 0000-0001-7681-9424
Marc HafnerDepartment of Oncology Bioinformatics, Genentech, Inc., South San Francisco, California.ORCID 0000-0003-1337-7598
Jason OehDepartment of Translational Oncology, Genentech, Inc., South San Francisco, California.
Mark MerchantDepartment of Translational Oncology, Genentech, Inc., South San Francisco, California.
Deepak SampathDepartment of Translational Oncology, Genentech, Inc., South San Francisco, California.
Michelle A NanniniDepartment of Translational Oncology, Genentech, Inc., South San Francisco, California.
Rebecca HongDepartment of Translational Oncology, Genentech, Inc., South San Francisco, California.
Lilian PhuDepartment of Microchemistry, Proteomics & Lipidomics, Genentech, Inc., South San Francisco, California.
William F ForrestDepartment of Oncology Bioinformatics, Genentech, Inc., South San Francisco, California.ORCID 0000-0002-0979-333X
Eric StawiskiDepartment of Oncology Bioinformatics, Genentech, Inc., South San Francisco, California.
Stephen SchmidtDepartment of Biochemical and Cell Pharmacology, Genentech, Inc., South San Francisco, California.
Nicholas EndresDepartment of Biochemical and Cell Pharmacology, Genentech, Inc., South San Francisco, California.
Jane GuanDepartment of Discovery Oncology, Genentech, Inc., South San Francisco, California.
Jeffrey J WallinDepartment of Translational Oncology, Genentech, Inc., South San Francisco, California.
Jonathan CheongDepartment of Translational Oncology, Genentech, Inc., South San Francisco, California.
Emile G PliseDepartment of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California.
Gail D Lewis PhillipsDepartment of Discovery Oncology, Genentech, Inc., South San Francisco, California.ORCID 0000-0001-7051-016X
Laurent SalphatiDepartment of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California.
Timothy P HeffronDepartment of Discovery Chemistry, Genentech, Inc., South San Francisco, California.
Alan G OliveroDepartment of Discovery Chemistry, Genentech, Inc., South San Francisco, California.
Shiva MalekDepartment of Discovery Oncology, Genentech, Inc., South San Francisco, California.ORCID 0000-0002-9526-7968
Steven T StabenDepartment of Discovery Chemistry, Genentech, Inc., South San Francisco, California.
Donald S KirkpatrickDepartment of Microchemistry, Proteomics & Lipidomics, Genentech, Inc., South San Francisco, California.
Anwesha DeyDepartment of Discovery Oncology, Genentech, Inc., South San Francisco, California. dey.anwesha@gene.com lorisfriedman123@gmail.com.
Lori S FriedmanDepartment of Translational Oncology, Genentech, Inc., South San Francisco, California. dey.anwesha@gene.com lorisfriedman123@gmail.com.ORCID 0000-0001-9127-9892
Discovery Centre · CATranslational Research in Oncology · FRBioinformatics Institute · SGBiochemical Society · GBMicrosemi (Canada) · CASunesis (United States) · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antineoplastic AgentsBreast NeoplasmsClass I Phosphatidylinositol 3-KinasesErb-b2 Receptor Tyrosine KinasesImidazolesOxazepinesPhosphoinositide-3 Kinase InhibitorsCell Line, TumorFemaleHumansOxazoles2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamideAntineoplastic AgentsClass I Phosphatidylinositol 3-KinasesErb-b2 Receptor Tyrosine KinasesImidazolesinavolisibOxazepinesOxazolesPhosphoinositide-3 Kinase InhibitorsPIK3CA protein, human
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.